Sovran Advisors LLC Acquires New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Sovran Advisors LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 113,457 shares of the biopharmaceutical company's stock, valued at approximately $2,867,000. Sovran Advisors LLC owned approximately 0.17% of Celldex Therapeutics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. KBC Group NV boosted its stake in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 495 shares in the last quarter. AQR Capital Management LLC boosted its stake in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after buying an additional 1,504 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its stake in Celldex Therapeutics by 5.1% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company's stock worth $1,449,000 after purchasing an additional 2,070 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in Celldex Therapeutics by 23.2% in the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company's stock worth $469,000 after purchasing an additional 2,600 shares in the last quarter. Finally, Values First Advisors Inc. boosted its stake in Celldex Therapeutics by 13.4% in the third quarter. Values First Advisors Inc. now owns 24,172 shares of the biopharmaceutical company's stock worth $822,000 after purchasing an additional 2,853 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms have commented on CLDX. UBS Group began coverage on Celldex Therapeutics in a research note on Thursday. They issued a "buy" rating and a $44.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $60.22.

Celldex Therapeutics Price Performance

Shares of CLDX stock traded down $0.36 on Friday, reaching $22.70. 460,616 shares of the stock were exchanged, compared to its average volume of 1,000,791. The stock has a market cap of $1.51 billion, a PE ratio of -8.83 and a beta of 1.60. Celldex Therapeutics, Inc. has a one year low of $20.91 and a one year high of $53.18. The stock has a 50 day moving average price of $24.79 and a 200 day moving average price of $29.98.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.